Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Susan O’Brien, Ian W. Flinn et al.|New England Journal of Medicine|2013Cited by 2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic LeukemiaRichard R. Furman, Susan O’Brien, Jeff P. Sharman et al.|New England Journal of Medicine|2014Cited by 1.7k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell MalignanciesRanjana H. Advani, Nathan Fowler, Joseph J. Buggy et al.|Journal of Clinical Oncology|2012Cited by 1.1k
The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II StudySusan O’Brien, John C. Byrd, Jan A. Burger et al.|Blood|2011Cited by 56
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignanciesJohn N. Allan, Jennifer R. Brown, Javier Pinilla‐Ibarz et al.|Haematologica|2021Cited by 37